Consort Medical Acquires the Medical House

Consort Medical enters the fast-growing auto-injection sector with its £16.8-million acquisition of the Medical House. Prior to the acquisition, expert appraisal of the technology portfolio and due diligence was conducted by Cambridge Consultants, the product design and development and technical consulting company, which has experience in the design and development of drug delivery devices.

Consort Medical focuses on technologies for drug delivery and hospital products for the management of patient airways. Through its Bespak business, the company has a leading position in the manufacture of inhaled drug delivery devices for pharmaceutical partner companies as well as a significant emerging business in metered dose inhaler dose counters.

The Medical House has developed a proprietary range of injection device technologies including auto-injectors and needle-free injection devices. It has been successful in securing a number of pharmaceutical partner licensing deals for its products.

Commenting on the acquisition, Jon Glenn, Chief Executive Officer of Consort Medical, said, “The Medical House will become part of Consort Medical’s Bespak division, bringing new expertise in the design of auto-injectors, an exciting and fast-growing self-injection technology driven by the significant increase in use of injectable biologic drugs.

The Medical House also brings a newly launched product as well as three important device development programmes on behalf of pharmaceutical company clients that are scheduled for launch in the next two years. The incremental revenue from these launches alone is exciting, but the combination of Bespak’s scale and manufacturing experience with the Medical House’s proprietary drug delivery technologies and design capabilities will offer an increasingly compelling solution to the pharmaceutical industry.”

Tags: Auto-injection drug delivery, Consort Medical